Immunocore Holdings plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMCR research report →
Range $35 – $43
Price Chart
About the company
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized.
- CEO
- Bahija Jallal
- IPO
- 2021
- Employees
- 524
- HQ
- Abingdon, OX, GB
Get TickerSpark's AI analysis on IMCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.36B
- P/E
- -41.55
- Fwd P/E
- 11.65
- PEG
- 0.51
- P/S
- 3.16
- P/B
- 3.23
- EV/EBITDA
- -749.84
- Div Yield
- 0.00%
- Gross Margin
- 98.86%
- Op Margin
- -6.76%
- Net Margin
- -7.48%
- ROE
- -7.96%
- ROIC
- -3.22%
Latest fiscal year · YoY change
- Revenue
- $400.02M+28.8%
- Gross Profit
- $391.66M+29.0%
- Op Income
- $-45,353,000
- Net Income
- $-35,514,000+30.5%
- EPS
- $-0.71+30.1%
- OCF Growth
- -141.1%
- FCF Growth
- -172.1%
- 52W High
- $40.72
- 52W Low
- $25.61
- 50D MA
- $30.49
- 200D MA
- $31.49
- Beta
- 0.81
- RSI (14)
- 33
- Avg Volume
- 447.50K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Immunocore reported solid KIMMTRAK growth, strong cash, and reiterated that multiple late-2026 to 2027 pipeline catalysts remain on track, led by TEBE-AM and broader melanoma expansion.· August 6, 2026
- KIMMTRAK generated $223 million in first-half 2026 net revenue, up 16% year over year; Q2 net sales were $116 million, up 18% year over year.
- The company said U.S. Q2 sales were $75 million, helped by about $6 million of distributor stocking that will create a Q3 headwind.
- Management reiterated that TEBE-AM top-line data could come as early as end-2026, with enrollment now in the teens from completion; ATOM and PRISM-MEL-301 also remain active.
- Five-year OS data showed 16% survival at five years for KIMMTRAK versus 8% for investigator’s choice, which management said supports first-line use in HLA-A*02:01-positive metastatic uveal melanoma.
- Cash and marketable securities were $880 million at June 30, and management expects about $120 million in sales-related rebates in the second half of 2026.
Immunocore said first-half 2026 KIMMTRAK net revenue was $223 million, up 16% versus the first half of 2025. Q2 net sales were $116 million, up 18% year over year, with the U.S. contributing $75 million (+17% year over year), Europe $34 million, and international regions $7 million. Q2 R&D was $74 million versus $69 million a year ago; SG&A was $44 million versus $43 million. Net loss was just under $1 million versus a $10 million loss in the prior-year quarter. Cash and marketable securities were $880 million at June 30, up $16 million from the start of the year. Management reiterated full-year/near-term commentary rather than formal revenue guidance: Q3 will face a headwind from about $6 million of U.S. stocking, KIMMTRAK sales growth is expected to moderate as penetration is high, and TEBE-AM headline data could be available as early as end-2026 if timing holds. The company also expects about $120 million of sales-related rebates in the second half of 2026, with 2027 rebate payments expected to normalize closer to 2025 levels.
Bahija Jallal framed the quarter as continued execution across three priorities: maximizing KIMMTRAK, advancing melanoma programs, and expanding into infection and autoimmune diseases. Her tone was upbeat and mission-driven, emphasizing the five-year survival result as proof of KIMMTRAK’s value and highlighting multiple upcoming catalysts, including TEBE-AM, PRAME data, and the first autoimmune patient dosing. She repeatedly stressed that the company remains on track across commercial and pipeline goals.
Travis Coy focused on the financial profile: Q2 KIMMTRAK sales were $116 million, up 18% year over year, with the U.S. at $75 million, Europe at $34 million, and international at $7 million. He noted that about $6 million of U.S. wholesaler stocking boosted the quarter and that underlying sequential growth was 3% after normalizing for that effect. R&D rose to $74 million from $69 million, SG&A was $44 million versus $43 million, and net loss narrowed to just under $1 million. He said cash and marketable securities totaled $880 million and flagged roughly $120 million of sales-related rebates in the second half of the year, driven by Europe growth and the France pricing agreement, with payments expected to return to more typical levels in 2027.
Analyst questions centered on whether TEBE-AM’s late-2026 readout depends on an interim analysis, what could push it into 2027, and how to think about the event curve. Management said the protocol may include an interim analysis, but the company does not plan data analysis until enrollment is complete, and the earliest possible headline readout remains end-2026. On KIMMTRAK, management clarified that “moderating growth” refers mainly to slower sequential growth, not the 17% year-over-year U.S. increase, and said U.S. penetration is above 70% with about 70% of prescriptions from the community; Europe is about 75%–80% penetrated. Questions also covered competition from Ideaya, ctDNA monitoring, and how the company views PRAME-HLE and ovarian/lung data; management said KIMMTRAK remains the first-line standard in HLA-A*02:01-positive uveal melanoma, while ctDNA use varies by institution and the PRAME-HLE and ovarian/lung datasets will help define next steps.
The call showed KIMMTRAK continuing to grow despite high market penetration, with management still seeing room in the community setting and in geographic expansion. The five-year OS data strengthens the product’s clinical narrative, and the company has multiple shots on goal in melanoma plus early-stage optionality in autoimmune disease and HIV.
Management repeatedly acknowledged that KIMMTRAK growth is likely to moderate because penetration is already high, and Q3 will face a stocking-related headwind. The TEBE-AM catalyst still depends on enrollment completion and event timing, while several pipeline programs remain early and data readouts are not until later in 2026 and 2027. The company also flagged a larger-than-usual $120 million rebate cash outflow in the second half of 2026.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.1%
- Shares Outstanding
- 51.64M
- Float Shares
- 46.02M
of shares held by institutions
145 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Wellington Management Group Llp | 5.72M | ▲ 1.02M |
| Rtw Investments, LP | 4.87M | 0 |
| Primecap Management Co | 3.64M | ▼ 2.39K |
| Bellevue Group AG | 2.79M | ▼ 8.56K |
| Tang Capital Management LLC | 2.65M | 0 |
| Acadian Asset Management LLC | 1.82M | ▲ 614.56K |
| Vestal Point Capital, LP | 1.80M | ▼ 966.87K |
| Fmr LLC | 1.74M | ▼ 2.57M |
| Two Sigma Investments, LP | 1.65M | ▲ 627.72K |
| Millennium Management LLC | 1.60M | ▲ 359.63K |
| Armistice Capital, LLC | 1.43M | ▲ 240.00K |
| Caligan Partners LP | 1.38M | ▲ 1.38M |
Held by 52 ETFs
Biggest fund positions in IMCR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 26 | Ratcliffe Peter John | other | 27,492 |
| May 27, 26 | Peterson Kristine | other | 27,492 |
| May 27, 26 | Pao William | other | 27,492 |
| May 27, 26 | Kaul Siddharth | other | 27,492 |
| May 27, 26 | Herbst Roy Steven | other | 27,492 |
| May 27, 26 | Bell John Irving | other | 27,492 |
| Feb 17, 26 | Coy Travis Alan | other | 95,637 |
| Feb 17, 26 | Coy Travis Alan | other | 33,353 |
| Feb 17, 26 | Jallal Bahija | other | 395,066 |
| Feb 17, 26 | Jallal Bahija | other | 88,573 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMCR coverage
Recent articles, reports, and earnings notes.
Want a deeper read on IMCR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Immunocore Holdings plc (IMCR) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Immunocore to present at upcoming investor conferences
globenewswire.com · Nov 9
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
globenewswire.com · Nov 6
Immunocore reports third quarter financial results and provides a business update
globenewswire.com · Nov 6
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
globenewswire.com · Oct 29
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
globenewswire.com · Oct 15
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
zacks.com · Sep 15
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
